Patents Assigned to Cytoskeleton Inc.
  • Patent number: 10690573
    Abstract: The present disclosure provides methods for reducing the viscosity of a cell lysate or tissue lysate by: contacting the cell lysate or tissue lysate with a compressible and open-cell foam filter having a pore size from about 0.65 mm to about 1.22 mm, compressing the filter to recover the lysate absorbed in the filter, and collecting the filtered lysate; and also provides kits therefor.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: June 23, 2020
    Assignee: Cytoskeleton, Inc.
    Inventors: Kim Middleton, Soonjin Hong, Wai K. Law, Henrick Horita
  • Patent number: 10288636
    Abstract: The present disclosure provides devices which deliver fluids from several reservoirs to a reaction vessel and eventually to a waste chamber in a predetermined schedule. The device provides improved simplicity while improving operational robustness and flexibility.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: May 14, 2019
    Assignee: Cytoskeleton, Inc.
    Inventors: Ashley Middleton-Davis, Kim Middleton-Davis
  • Patent number: 9599629
    Abstract: The present disclosure provides devices which deliver fluids from several reservoirs to a reaction vessel and eventually to a waste chamber in a predetermined schedule. The device provides improved simplicity while improving operational robustness and flexibility.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 21, 2017
    Assignee: Cytoskeleton, Inc.
    Inventors: Ashley Middleton-Davis, Kim Middleton-Davis
  • Publication number: 20100240551
    Abstract: The present invention provides methods of detecting activated Rho GTPase proteins by contacting a solid support with a sample comprising an activated Rho GTPase protein. The solid support is linked to an activated Rho GTPase binding peptide. The activated Rho GTPase protein remains associated with the solid support during the detection.
    Type: Application
    Filed: June 2, 2010
    Publication date: September 23, 2010
    Applicant: CYTOSKELETON, INC.
    Inventors: Li Cheng, Ashley Davis, Kim Middleton
  • Patent number: 7763418
    Abstract: The present invention provides methods of detecting activated Rho GTPase proteins by contacting a solid support with a sample comprising an activated Rho GTPase protein. The solid support is linked to an activated Rho GTPase binding peptide. The activated Rho GTPase protein remains associated with the solid support during the detection.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: July 27, 2010
    Assignee: Cytoskeleton, Inc.
    Inventors: Li Cheng, Ashley Davis, Kim Middleton
  • Patent number: 7282571
    Abstract: In basic research and drug discovery there is a need to provide protein reagents with high activity. In particular proteins that are used in assays must have a good shelf life and a consistent activity. As a system of measuring actin polymerization, pyrene labeled actin was developed in 1983 by Kouyama and Mihashi. However, prior to this disclosure, pyrene actin has been impossible to store for longer than one month because the activity would be lost due to protein denaturation and frozen pyrene actin immediately lost activity. This disclosure relates a method for stabilizing pyrene labeled actin for extended storage times and an optimal storage buffer thus creating a reproducible source of pyrene actin for various assays. Using the processes described herein, pyrene actin has been stored for greater than 3 years at 4° C. which makes it a viable product for retail.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: October 16, 2007
    Assignee: Cytoskeleton Inc.
    Inventors: Ashley Stuart Davis, Kim Maria Middleton
  • Patent number: 7259278
    Abstract: It is presently accepted that the mechanism of action for all anti-tumor tubulin ligands involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (1). In this invention, we report a novel tubulin ligands which have a unique mechanism of action. These compounds, halogenated derivatives of acetamido benzoyl ethyl ester (HAABE), arrest cancer cells in S-phase and cause cell death by a combination of apoptosis (DNA ladder) and necrosis (DNA degradation) type mechanisms. Normal cells are not affected at the same concentrations of compound. The ligands bind covalently to tubulin in vitro and in vivo and shows potent cancericidal activity in tissue culture assays and in animal tumor models. These compounds target early S-phase at the G1/S transition rather than the G2/M phase and mitotic arrest.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: August 21, 2007
    Assignee: Cytoskeleton Inc.
    Inventors: Ashley Stuart Davis, Kim Maria Middleton, Jain Dong Jiang, J. George Bekesi
  • Patent number: D806262
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 26, 2017
    Assignee: Cytoskeleton, Inc.
    Inventors: Ashley Stuart Middleton-Davis, Kim Maria Middleton-Davis